Dantrolene Sodium USP
Composition : Dantrolene Sodium USP 25 mg.
Indication : In Chronic Spasticity : Dantrolene Sodium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy or multiple sclerosis. It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity
Dosage and administration : For use in Chronic Spasticity : Adults Patients : The following gradual titration schedule is suggested. Some patients will not respond until higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose. 25 mg once daily for seven days, then 25 mg 3 times for seven days, 50 mg 3 times for seven days, 100 mg 3 times. For
Use in pregnancy and lactation : Pregnancy Category C. Dantrolene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dantrolene should not be used in nursing mothers.
Packing : Trolen-25 : 2 x 10's capsules in blister pack.
